<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008656</url>
  </required_header>
  <id_info>
    <org_study_id>13-213</org_study_id>
    <nct_id>NCT02008656</nct_id>
  </id_info>
  <brief_title>Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management</brief_title>
  <official_title>A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Colon and Rectal Surgery Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>John Muir Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph Hospital of Orange</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bergan Mercy Medical Centere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph, Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cleveland Clinic Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Aurora</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The study is designed to test the hypothesis that patients with Locally advanced rectal
      cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision
      (TME) or Non-operative management (NOM) will have an improved 3-year disease-free survival
      (DFS) compared to patients with similar tumors treated with Chemoradiation therapy (CRT),
      Total mesorectal excision (TME) and Adjuvant chemotherapy (ACT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>3-year DFS will be defined as the percentage of patients alive without recurrence of disease at 3 years measured from the date of randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin (OXAL)</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5-FU)</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine (Xeloda®)</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity modulated radiotherapy (IMRT)</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DRE-Endoscopy</intervention_name>
    <arm_group_label>INCT</arm_group_label>
    <arm_group_label>CNCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of adenocarcinoma of the rectum

          -  Clinical Stage II (T3-4, N-) or Stage III (any T, N+) based on MRI

          -  Rectal tumor at baseline which would be considered to require complete TME

          -  No evidence of distant metastases

          -  No prior pelvic radiation therapy

          -  No prior chemotherapy or surgery for rectal cancer

          -  Age ≥ 18 years The minimum legal age of consent for select Canadian provinces is 19

          -  No active infections requiring systemic antibiotic treatment (oral antibiotics are
             acceptable at the discretion of the treating physician)

          -  ECOG Performance status 0-2

          -  Women with childbearing potential (WOCBP) who are negative for pregnancy test (urine
             or blood) and who agree to use effective contraceptive method. A woman of childbearing
             potential is defined of one who is biologically capable of becoming pregnant. Reliable
             contraception should be used from trial screening and must be continued throughout the
             study.

          -  Patients must read, agree to, and sign a statement of Informed Consent prior to
             participation in this study. Patients who do not read or understand English are
             eligible and may be consented according to institutional and federal regulations.

          -  ANC &gt; 1.5 cells/mm3, HGB &gt; 8.0 gm/dl, PLT &gt; 150,000/mm3 total bilirubin ≤ 1.5 x ULN
             (except in patients with Gilbert's Syndrome who must have total bilirubin ≤ 3.0 x
             ULN), AST≤ 3 x ULN, ALT ≤ 3 x ULN.

        Exclusion Criteria:

          -  Recurrent rectal cancer

          -  Primary unresectable rectal cancer. A tumor is considered unresectable when invading
             adjacent organs and an en block resection will not achieve negative margins.

          -  Creatinine level greater than 1.5 times the upper limit of normal.

          -  Patients who have received prior pelvic radiotherapy.

          -  Patients who are unable to undergo an MRI.

          -  Patients with a history of any arterial thrombotic event within the past 6 months.
             This includes angina (stable or unstable), MI, TIA, or CVA.

          -  Patients with a history of venous thrombotic episodes such as deep venous thrombosis,
             pulmonary embolus occurring more than 6 months prior to enrollment may be considered
             for protocol participation, provided they are on stable doses of anticoagulant
             therapy. Similarly, patients who are anticoagulated for atrial fibrillation or other
             conditions may participate, provided they are on stable doses of anticoagulant
             therapy.

          -  Other Anticancer or Experimental Therapy. No other experimental therapies (including
             chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene
             therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors,
             thalidomide, anti-VEGF/Flk-1 monoclonal antibody or other experimental drugs) of any
             kind are permitted while the patient is receiving study treatment.

          -  WOCBP who are unwilling or unable to use an acceptable method of avoiding pregnancy
             for the entire study period.

          -  Women who are pregnant or breast-feeding.

          -  Patients with any other concurrent medical or psychiatric condition or disease which,
             in the investigator's judgment, would make them inappropriate candidates for entry
             into this study.

          -  Patients with a history of a prior malignancy within the past 5 years, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Garcia Aguilar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julio Garcia Aguilar, MD PhD</last_name>
    <phone>212-639-5117</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonard Saltz, MD</last_name>
    <phone>646-888-4181</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3849</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhulika Varma, MD</last_name>
      <phone>415-885-3606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Muir Health</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Oommen, MD</last_name>
      <phone>925-274-9000</phone>
    </contact>
    <investigator>
      <last_name>Samuel Oommen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ayscue, MD</last_name>
      <phone>202-877-8484</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Ayscue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Marcet, MD</last_name>
      <phone>813-259-0925</phone>
    </contact>
    <investigator>
      <last_name>Jorge Marcet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Weiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter O'Donnell, MD</last_name>
      <phone>888-824-0200</phone>
    </contact>
    <investigator>
      <last_name>Peter O'Donnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Northville</city>
        <state>Michigan</state>
        <zip>48168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Krauss, MD</last_name>
      <phone>248-305-4400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hunt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Hunt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Heath Bergan Mercy</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Ternent, MD</last_name>
      <phone>402-343-1122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colon and Rectal Surgery, Incorporated</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Ternent, MD</last_name>
      <phone>402-343-1122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia Aguilar, MD, PhD</last_name>
      <phone>212-639-5117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia Aguilar, MD, PhD</last_name>
      <phone>212-639-5117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering West Harrison</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia-Aguilar, MD, PhD</last_name>
      <phone>212-639-5117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia-Aguilar, MD,PhD</last_name>
      <phone>212-639-5117</phone>
    </contact>
    <contact_backup>
      <last_name>Leonard Saltz, MD</last_name>
      <phone>646-888-4181</phone>
    </contact_backup>
    <investigator>
      <last_name>Julio Garcia-Aguilar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Tejani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mohammed Tejani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia Aguilar, MD, PhD</last_name>
      <phone>212-639-5117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center at Phelps</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Garcia Aguilar, MD, PhD</last_name>
      <phone>212-639-5117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Herzig, MD</last_name>
      <phone>503-494-4373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Cataldo, MD</last_name>
      <phone>802-847-1288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Friel, MD</last_name>
      <phone>434-243-9970</phone>
    </contact>
    <investigator>
      <last_name>Charles Friel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAPECITABINE (ORAL)</keyword>
  <keyword>FLUOROURACIL</keyword>
  <keyword>LEUCOVORIN</keyword>
  <keyword>OXALIPLATIN</keyword>
  <keyword>Total mesorectal excision</keyword>
  <keyword>Chemoradiation therapy</keyword>
  <keyword>Total neoadjuvant therapy</keyword>
  <keyword>13-213</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

